Today: 9 June 2026
NextNRG Shares Double as Record April Sales Drive Gains

NextNRG Shares Double as Record April Sales Drive Gains

NEW YORK, May 20, 2026, 08:01 EDT

NextNRG Inc. shares fell in premarket on Wednesday after surging yesterday. Traders focused on the company’s record April revenue, but concerns lingered over its low cash and the need to raise more money.

The stock, listed on Nasdaq, finished Tuesday at $0.8201, jumping 100.02%. Shares were at $0.73 before the bell at 8:01 a.m. EDT. The Nasdaq opens for regular trading at 9:30 a.m. EDT.

NextNRG said preliminary revenue for April jumped 56% from last year to $9.4 million, setting a record for monthly sales. The Miami Beach-based company reported gross profit up 64% to around $778,000. Gross margin ticked up to 8.3%, compared to 7.9%.

That’s key now as NextNRG looks to scale up its mobile fueling business and build out its broader push into energy infrastructure, including microgrids and wireless EV charging. Microgrids are local power systems, with some able to keep operating when the main grid has issues.

NextNRG CEO Michael Farkas said April saw the company’s best revenue month in a release out today, noting a continued push for “operational discipline” in its fueling and energy infrastructure work. The company flagged that the results are preliminary and haven’t been audited, so final figures could change. GlobeNewswire

NextNRG’s April update came after its latest quarter showed revenue growing but losses deepening. The company posted Q1 revenue of $21.1 million, a 29% jump year over year. Gross profit was $1.7 million, over three times last year’s figure. Net loss increased to $10.8 million from $8.9 million.

Adjusted EBITDA, which excludes things like interest, depreciation, and stock-based pay, came in at a loss of $1.16 million. That’s better than the $3.40 million loss posted earlier. The company said its operating loss factored in $7.86 million of non-cash stock-based compensation.

Margin gains reported on the May 18 earnings call were “structural rather than one time,” CFO Joel Kleiner said, pointing to route optimization, fleet use and customer density. CEO Farkas told analysts the company’s microgrid pipeline touched commercial, healthcare, industrial, municipal and federal customers. He noted those deals take longer to close. StockAnalysis

Complex mix in the fleet-fueling market. Booster delivers gasoline and diesel directly to fleets on-site. ChargePoint is more about hardware and software for EV charging and fleet management. NextNRG is in between—making money from mobile fueling now, but also looking to microgrids and wireless charging in the future.

Capital is a problem. NextNRG’s latest quarterly filing showed $208,048 in cash on March 31, with a working-capital deficit of $25.0 million and an accumulated deficit at $164.7 million. The company said it needs new capital right away and warned there is substantial doubt it can keep operating as a going concern, an accounting term for when a company may not have enough funding to survive.

Listing pressure is in play too. Nasdaq notified NextNRG in March it had fallen below the $1 minimum bid-price requirement. The company has until Sept. 14, 2026 to fix it. Trading isn’t affected now, but NextNRG said there’s no guarantee it gets back into compliance.

Investors are watching to see if April’s jump in revenue signals a lasting shift or is just another swing in this volatile micro-cap. The real test will be audited numbers showing stronger sales and margins, along with signs that NextNRG can keep running without leaning harder on its current shareholders.

Stock Market Today

  • Semiconductor Stock Poised to Surpass Micron Technology by 2028
    June 9, 2026, 10:18 AM EDT. Micron Technology has surged nearly 800% recently, driven by high demand and pricing power in memory chips, pushing its market cap past $1 trillion. However, analysts predict supply constraints easing by 2028 could cause earnings to peak and decline, potentially halving share value to around $517.50. Meanwhile, a major semiconductor competitor valued around $650 billion is expanding production, potentially surpassing Micron's value by 2028. The industry faces cyclical dynamics as new manufacturing capacity comes online globally, impacting pricing and earnings. Investors are watching these shifts closely for long-term positioning amid evolving chip supply and demand.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Micware Shares Swing Pre-Market After 26% Drop on Nasdaq Debut
Previous Story

Micware Shares Swing Pre-Market After 26% Drop on Nasdaq Debut

Intuit’s Q3 Numbers Land as Shares Down 39%
Next Story

Intuit’s Q3 Numbers Land as Shares Down 39%

Go toTop